DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Information source: Chinese Academy of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Triple Negative Breast Cancer

Intervention: Paclitaxel plus carboplatin (Drug); Paclitaxel and epirubicin (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Chinese Academy of Medical Sciences

Official(s) and/or principal investigator(s):
ZHANG Pin, BD, Principal Investigator, Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Overall contact:
ZHANG Pin, BD, Phone: +861087788120, Email: zhang_pin@sina.com

Summary

This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC. And the investigators hypothesized that paclitaxel combined with carboplatin is more sensitive to TNBC compared with Paclitaxel plus Epirubicin,this study will also have a look into the relation of BRCA1 mutation and sensitive to carboplatin.

Clinical Details

Official title: Phase IIb Trial of Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Epirubicin as Neoadjuvant Treatment in Locally Advanced Triple-negative Breast Cancer

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Pathology of specimens derived from the breast modified radical mastectomy/Breast-conserving surgery

Secondary outcome: follow-up the patient every 3-6 months to obtain the 3 year-DFS(disease free survival ) and OS(overall survival )

Detailed description: It is know that triple-negative breast cancer(TNBC) is more aggressive than non-triple negative breast cancer in both pathological features and clinical prognosis,and there is no standard chemotherapy regimens especially for TNBC. NCCN guidelines recommends Paclitaxel or Epirubicin based regimens as the preferred regimens both for the adjuvant chemotherapy and the treatment of Recurrence and Metastatic breast cancer. The combination of these two drugs is considered as a strong arrangement and therefore,is common used in Triple negative breast cancer patients because of its poor prognosis. According to the results of some retrospective studies, platinum-based chemotherapy regimens showed a promising sensitive to Triple negative breast cancer patients compared with regimens without platinum. This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC. And the investigators hypothesized that paclitaxel combined with carboplatin is more sensitive to TNBC compared with Paclitaxel plus Epirubicin,this study will also have a look into the relation of BRCA1 mutation and sensitive to carboplatin.

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Women aged from 18 to 70 years;

- WHO Performance status (ECOG) of 0 or 1

- Core biopsy histologically proven Ⅱa-Ⅲc phase breast cancer (regardless of the type);

- Immunohistochemisty(IHC):ER-,PR-,CerB2-;Triple negative (ER-PR-Her-2-) Hormone

receptor negativity is defined as ER<10%, PR<10% (IHC), HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH negative];

- Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x

109/l, Hemoglobin > 9 g/dl);

- Adequate hepatic function: ASAT and ALAT £ 1. 5 ULN alkaline phosphatases £ 2. 5

ULN,total bilirubin £ 1,5 ULN;

- Adequate renal function: serum creatinine £ 1. 5 ULN;

- Adequate cardiac function, LEVF value > 50% by Muga scan or echocardiography,and

electrocardiogram doe not show specific abnormality;

- Patients accepting contraception intake during the overall length of treatment if of

childbearing potential;

- Signed written informed consent.

Exclusion Criteria:

- Any tumor ³ T4a (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast

cancer);

- ER+ or PR+ or Her-2 overexpression

- Any chemotherapy, hormonal therapy or radiotherapy before

- Previous cancer in the preceding 10 years;

- Patients already included in another therapeutic trial involving an experimental

drug;

- Patients with other concurrent severe and/or uncontrolled medical disease or

infection which could compromise participation in the study;

- LEVF < 50% (MUGA scan or echocardiography);

- Clinically significant cardiovascular disease (e. g. unstable angina, congestive heart

failure, uncontrolled hypertension (>150/90), myocardial infarction or cerebral vascular accidents) within 6 months prior to chemotherapy;

- Known prior severe hypersensitivity reactions to agents that will be received;

- Women who are pregnant or breastfeeding. Adequate birth control measures should be

taken during study treatment phase;

- Women with a positive pregnancy test en enrollment or prior to study drug

administration;

- Patients with any psychological, familial, sociological or geographical condition

potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;

- Individual deprived of liberty or placed under the authority of a tutor.

Locations and Contacts

ZHANG Pin, BD, Phone: +861087788120, Email: zhang_pin@sina.com

Cancer institute &Hospital,Chinese Academy of Medical Sciences, Beijing, Beijing 100021, China; Recruiting
ZHANG Pin, BD, Phone: +861087788120, Email: zhang_pin@163.com
YIN Yi, BD, Email: elovf1@163.com
ZHANG Pin, BD, Principal Investigator
Additional Information

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Starting date: January 2008
Last updated: November 15, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017